Access the full text.
Sign up today, get DeepDyve free for 14 days.
W. Elliott (2012)
Better compliance to antihypertensive medications reduces cardiovascular riskYearbook of Cardiology, 2012
(2020)
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: the Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)Eur Heart J, 41
(2018)
2018 ESC/ESH Guidelines for the management of arterial hypertensionEur Heart J, 39
B. Ibáñez, Stefan James, S. Agewall, M. Antunes, C. Bucciarelli-Ducci, H. Bueno, A. Caforio, F. Crea, J. Goudevenos, S. Halvorsen, G. Hindricks, A. Kastrati, M. Lenzen, E. Prescott, M. Roffi, M. Valgimigli, C. Varenhorst, P. Vranckx, Petr Widimsky (2018)
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).European heart journal, 39 2
P. Heidenreich, B. Bozkurt, D. Aguilar, L. Allen, Joni Byun, Monica Colvin, A. Deswal, M. Drazner, S. Dunlay, Linda Evers, J. Fang, S. Fedson, G. Fonarow, S. Hayek, Adrian Hernandez, P. Khazanie, M. Kittleson, Christopher Lee, M. Link, C. Milano, Lorraine Nnacheta, Alexander Sandhu, L. Stevenson, O. Vardeny, A. Vest, C. Yancy (2022)
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.Circulation
F. Arós, Á. Loma-Osorio, J. Vila, L. López-Bescós, J. Cuñat, Emilio Rodríguez, J. José, M. Heras, J. Marrugat (2006)
Efecto de la asociación de bloqueadores beta e inhibidores de la enzima de conversión en la supervivencia al año tras un infarto agudo de miocardio. Resultados del registro PRIAMHO IIRevista Espanola De Cardiologia, 59
M. Vincent, G. Remond, B. Portevin, B. Serkiz, M. Laubie (1982)
Stereoselective synthesis of a new perhydroindole derivative of chiral iminodiacid, a potent inhibitor of angiotensin converting enzymeTetrahedron Letters, 23
B. Lévy, J. Mourad (2021)
Renin Angiotensin blockers and cardiac protection. From basis to clinical trials.American journal of hypertension
S. Julius, P. Palatini, S. Kjeldsen, A. Zanchetti, Michael Weber, Gordon Mcinnes, Hans Brunner, G. Mancia, M. Schork, T. Hua, B. Holzhauer, D. Zappe, S. Majahalme, K. Jamerson, N. Koylan (2012)
Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension.The American journal of cardiology, 109 5
G. Tsoukas, S. Anand, Kwang Yang, Confidence Investigators (2011)
Dose-Dependent Antihypertensive Efficacy and Tolerability of Perindopril in a Large, Observational, 12-Week, General Practice-Based StudyAmerican Journal of Cardiovascular Drugs, 11
K. Fox (2003)
Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)The Lancet, 362
M. Sabidó, Hohenberger Thilo, G. Guido (2019)
Long‐term effectiveness of bisoprolol in patients with angina: A real‐world evidence studyPharmacological Research, 139
Lin Zp, M. Dong, Jian Liu (2013)
Bisoprolol improved endothelial function and myocardium survival of hypertension with stable angina: a randomized double-blinded trial.European review for medical and pharmacological sciences, 17 6
Amanda Black, A. Adler, L. Agodoa, A. Algra, F. Asselbergs, N. Beckett, E. Berge, H. Black, F. Brouwers, Morris Brown, C. Bulpitt, R. Byington, J. Chalmers, W. Cushman, J. Cutler, B. Davis, R. Devereaux, J. Dwyer, R. Estacio, R. Fagard, K. Fox, T. Fukui, Ajay Gupta, R. Holman, Y. Imai, M. Ishii, S. Julius, Y. Kanno, S. Kjeldsen, J. Kostis, K. Kuramoto, J. Lanke, E. Lewis, J. Lewis, M. Lièvre, L. Lindholm, S. Lueders, S. MacMahon, G. Mancia, M. Matsuzaki, M. Mehlum, S. Nissen, H. Ogawa, T. Ogihara, T. Ohkubo, C. Palmer, Anushka Patel, C. Pepine, M. Pfeffer, B. Pitt, N. Poulter, H. Rakugi, Giuseppe Reboldi, C. Reid, G. Remuzzi, P. Ruggenenti, T. Saruta, J. Schrader, R. Schrier, P. Sever, P. Sleight, J. Staessen, Hiromichi Suzuki, L. Thijs, K. Ueshima, S. Umemoto, W. Gilst, P. Verdecchia, K. Wachtell, P. Whelton, L. Wing, M. Woodward, Y. Yui, S. Yusuf, A. Zanchetti, Zhenyu Zhang, C. Anderson, C. Baigent, B. Brenner, R. Collins, D. Zeeuw, J. Lubsen, E. Malacco, B. Neal, V. Perkovic, A. Rodgers, P. Rothwell, G. Salimi-Khorshidi, J. Sundström, F. Turnbull, G. Viberti, Jiguang Wang (2021)
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysisLancet (London, England), 397
B. Williams, G. Mancia, W. Spiering, E. Rosei, M. Azizi, M. Burnier, D. Clement, A. Coca, G. Simone, A. Dominiczak, T. Kahan, F. Mahfoud, J. Redón, L. Ruilope, A. Zanchetti, M. Kerins, S. Kjeldsen, R. Kreutz, S. Laurent, G. Lip, R. McManus, K. Narkiewicz, F. Ruschitzka, R. Schmieder, E. Shlyakhto, C. Tsioufis, V. Aboyans, I. Desormais (2019)
[2018 ESC/ESH Guidelines for the management of arterial hypertension].Kardiologia polska, 77 2
F. Cosentino, P. Grant, V. Aboyans, Clifford Bailey, A. Ceriello, V. Delgado, M. Federici, G. Filippatos, D. Grobbee, T. Hansen, H. Huikuri, I. Johansson, P. Jüni, M. Lettino, N. Marx, L. Mellbin, C. Östgren, B. Rocca, M. Roffi, N. Sattar, P. Seferovic, M. Sousa‐Uva, P. Valensi, D. Wheeler (2019)
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.European heart journal
D. Ettehad, C. Emdin, A. Kiran, S. Anderson, T. Callender, J. Emberson, J. Chalmers, A. Rodgers, K. Rahimi (2016)
Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysisThe Lancet, 387
(World Health Organization. The selection and use of essential medicines 2019. https://www.who.int/publications/i/item/WHO-MVP-EMP-IAU-2019.05. Accessed 3 Feb 2023.)
World Health Organization. The selection and use of essential medicines 2019. https://www.who.int/publications/i/item/WHO-MVP-EMP-IAU-2019.05. Accessed 3 Feb 2023.World Health Organization. The selection and use of essential medicines 2019. https://www.who.int/publications/i/item/WHO-MVP-EMP-IAU-2019.05. Accessed 3 Feb 2023., World Health Organization. The selection and use of essential medicines 2019. https://www.who.int/publications/i/item/WHO-MVP-EMP-IAU-2019.05. Accessed 3 Feb 2023.
J. Knuuti, W. Wijns, A. Saraste, D. Capodanno, E. Barbato, C. Funck-Brentano, E. Prescott, R. Storey, C. Deaton, T. Cuisset, S. Agewall, K. Dickstein, T. Edvardsen, J. Escaned, B. Gersh, P. Svítil, M. Gilard, D. Hasdai, R. Hatala, F. Mahfoud, J. Masip, C. Muneretto, M. Valgimigli, S. Achenbach, Jeroen Bax (2020)
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromesRevista Española de Cardiología (English Edition)
T. Arnim (1995)
Medical treatment to reduce total ischemic burden : total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipineJournal of the American College of Cardiology, 25
(2014)
2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice GuidelinesCirculation, 130
C. Pratt, R. Mcmahon, S. Goldstein, C. Pepine, T. Andrews, I. Dyrda, W. Frishman, N. Geller, J. Hill, N. Morgan, P. Stone, G. Knatterud, G. Sopko, C. Conti (1996)
Comparison of subgroups assigned to medical regimens used to suppress cardiac ischemia (the Asymptomatic Cardiac Ischemia Pilot [ACIP] Study).The American journal of cardiology, 77 15
E. Amsterdam (2015)
A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
W. Elliott (2010)
Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 TrialsYearbook of Cardiology, 2010
A. Eisen, Deepak Bhatt, P. Steg, K. Eagle, S. Goto, Jianping Guo, Sidney Smith, E. Ohman, B. Scirica (2016)
Angina and Future Cardiovascular Events in Stable Patients With Coronary Artery Disease: Insights From the Reduction of Atherothrombosis for Continued Health (REACH) RegistryJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 5
Jasper Brugts, Michel Bertrand, W. Remme, Roberto Ferrari, K. Fox, S. MacMahon, John Chalmers, M. Simoons, E. Boersma (2017)
The Treatment Effect of an ACE-Inhibitor Based Regimen with Perindopril in Relation to Beta-Blocker use in 29,463 Patients with Vascular Disease: a Combined Analysis of Individual Data of ADVANCE, EUROPA and PROGRESS TrialsCardiovascular Drugs and Therapy, 31
W. Kop, R. Verdino, J. Gottdiener, S. O’Leary, C. Merz, David Krantz (2001)
Changes in heart rate and heart rate variability before ambulatory ischemic eventsJournal of the American College of Cardiology, 38
J. Collet, H. Thiele, E. Barbato, O. Barthelemy, J. Bauersachs, Deepak Bhatt, P. Dendale, M. Dorobanțu, T. Edvardsen, T. Folliguet, C. Gale, M. Gilard, A. Jobs, P. Jüni, E. Lambrinou, B. Lewis, J. Mehilli, E. Meliga, B. Merkely, C. Mueller, M. Roffi, F. Rutten, D. Sibbing, G. Siontis (2020)
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.European heart journal
(2021)
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEur Heart J, 42
G. Sinagra, L. Pagura, D. Stolfo (2022)
[ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: what's new?]Giornale italiano di cardiologia, 23 1
J. Beltrame, A. Weekes, C. Morgan, R. Tavella, J. Spertus (2009)
The prevalence of weekly angina among patients with chronic stable angina in primary care practices: The Coronary Artery Disease in General Practice (CADENCE) Study.Archives of internal medicine, 169 16
(2015)
Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of HypertensionHypertension, 65
M. Strauss, A. Hall, K. Narkiewicz (2021)
The Combination of Beta-Blockers and ACE Inhibitors Across the Spectrum of Cardiovascular DiseasesCardiovascular Drugs and Therapy, 37
M. Bertrand, R. Ferrari, W. Remme, M. Simoons, K. Fox (2015)
Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis.American heart journal, 170 6
M. Esler, S. Kjeldsen, A. Pathak, G. Grassi, R. Kreutz, G. Mancia (2022)
Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justifiedBlood Pressure, 31
Jiabin Zang, Jianwen Liang, X. Zhuang, Shao-zhao Zhang, X. Liao, Guifu Wu (2021)
Intensive blood pressure treatment in coronary artery disease: implications from the Systolic Blood Pressure Intervention Trial (SPRINT)Journal of Human Hypertension, 36
(2008)
The selection and use of essential medicines.World Health Organization technical report series, 965
J. Knuuti (2020)
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)Russian Journal of Cardiology
aguda crónica (2022)
Comments on the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure.Revista espanola de cardiologia
T. Arnim (1995)
Medical treatment to reduce total ischemic burden: total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. The TIBBS Investigators.Journal of the American College of Cardiology, 25 1
R. Ogilvie, S. Anand, P. Roy, Selwyn Souza (2008)
Perindopril for Control of Blood Pressure in Patients with Hypertension and Other Cardiovascular Risk FactorsClinical Drug Investigation, 28
J. Gore (2015)
Treatment of Hypertension in Patients with Coronary Artery DiseaseNEJM Journal Watch, 2015
R. Carney, K. Freedland (2022)
Polypill Strategy in Secondary Cardiovascular Prevention.The New England journal of medicine, 387 23
Tsuyoshi Morishita, M. Tsutsui, H. Shimokawa, H. Tasaki, Osamu Suda, Kengo Kobayashi, Masataka Horiuchi, Haruhito Okuda, Y. Tsuda, N. Yanagihara, Y. Nakashima (2002)
Long-term treatment with perindopril ameliorates dobutamine-induced myocardial ischemia in patients with coronary artery disease.Japanese journal of pharmacology, 88 1
L. Jespersen, S. Abildstrom, A. Hvelplund, E. Prescott (2013)
Persistent angina: highly prevalent and associated with long-term anxiety, depression, low physical functioning, and quality of life in stable angina pectorisClinical Research in Cardiology, 102
A. Jacobs, F. Kushner, S. Ettinger, R. Guyton, Jeffrey Anderson, E. Ohman, N. Albert, E. Antman, D. Arnett, M. Bertolet, Deepak Bhatt, R. Brindis, M. Creager, D. DeMets, K. Dickersin, G. Fonarow, R. Gibbons, J. Halperin, J. Hochman, M. Koster, S. Normand, Eduardo Ortiz, E. Peterson, William Roach, R. Sacco, Sidney Smith, W. Stevenson, G. Tomaselli, C. Yancy, W. Zoghbi, J. Harold, Yulei He, P. Mangu, A. Qaseem, M. Sayre, M. Somerfield (2013)
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.Circulation, 127 4
Tianlun Yang, Yinong Jiang, Y. Hao, Shuxian Zhou, Xinjuan Xu, B. Qu, Xue Lin, T. Ma (2017)
Comparison of bisoprolol to a metoprolol CR/ZOK tablet for control of heart rate and blood pressure in mild-to-moderate hypertensive patients: the CREATIVE studyHypertension Research, 40
(2015)
in patients with coronary artery disease : a scientific statement from the American Heart Association , American College of Cardiology , and American Society of
Tu Nguyen, C. Chow (2021)
Global and national high blood pressure burden and controlThe Lancet, 398
Jihoon Kim, D. Kang, Hyejeon Park, Minwoong Kang, T. Park, J. Lee, Jeong Yang, Y. Song, Jin‐Ho Choi, Seung‐Hyuk Choi, H. Gwon, E. Guallar, Juhee Cho, J. Hahn (2020)
Long-term β-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study.European heart journal
G. Leopold (1985)
Balanced Pharmacokinetics and Metabolism of BisoprololJournal of Cardiovascular Pharmacology, 8
(2022)
Popylill strategy in secondary cardiovascular preventionN Engl J Med, 387
Z. Kobalava, Y. Khomitskaya, G. Kiyakbaev (2014)
AchievemenT of target resting HEart rate on beta-blockers in patients with stable angiNA and hypertension (ATHENA) in routine clinical practice in RussiaCurrent Medical Research and Opinion, 30
(2009)
Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trialsAm J Med, 122
Jules Mesnier, G. Ducrocq, N. Danchin, R. Ferrari, I. Ford, J. Tardif, M. Tendera, K. Fox, P. Steg (2021)
International Observational Analysis of Evolution and Outcomes of Chronic Stable AnginaCirculation, 144
T. Unger, C. Borghi, F. Charchar, Nadia Khan, N. Poulter, D. Prabhakaran, A. Ramirez, M. Schlaich, G. Stergiou, M. Tomaszewski, R. Wainford, B. Williams, A. Schutte (2020)
2020 International Society of Hypertension Global Hypertension Practice Guidelines.Hypertension
R. Ferrari, K. Fox (2016)
Heart rate reduction in coronary artery disease and heart failureNature Reviews Cardiology, 13
Treat - ment of
(2021)
Effectiveness and tolerability of the single-pill combination of bisoprolol and perindopril in patients with arterial hypertension and stable coronary artery disease in daily clinical practice: the STYLE studyAdv Ther, 38
T. Andrews, T. Fenton, N. Toyosaki, S. Glasser, Phillip Young, G. Maccallum, R. Gibson, T. Shook, P. Stone (1993)
Subsets of ambulatory myocardial ischemia based on heart rate activity. Circadian distribution and response to anti-ischemic medication. The Angina and Silent Ischemia Study Group (ASIS)Circulation, 88 1
P. Steg, N. Greenlaw, J. Tardif, M. Tendera, I. Ford, S. Kääb, H. Abergel, K. Fox, R. Ferrari (2012)
Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registryEuropean Heart Journal, 33
M. Abeel, Anil Gupta, C. Constance (2021)
Concomitant Treatment of Hypertensive Patients with Bisoprolol and Perindopril in Routine Clinical Practice: A Post Hoc Analysis of the CONFIDENCE II, PROTECT I, and PROTECT III Observational StudiesAdvances in Therapy, 39
T. Unger, C. Borghi, F. Charchar, Nadia Khan, N. Poulter, D. Prabhakaran, A. Ramirez, M. Schlaich, G. Stergiou, M. Tomaszewski, R. Wainford, B. Williams, A. Schutte (2020)
2020 International Society of Hypertension global hypertension practice guidelines.Journal of Hypertension
M. Law, J. Morris, N. Wald (2009)
Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studiesThe BMJ, 338
(2011)
Better compliance to antihypertensive medications reduces cardiovascular riskJ Hypertens, 29
(Arós F, Loma-Osorio A, Vila J, et al. Efecto de la asociación de bloqueadores beta e inhibidores de la enzima de conversión en la supervivencia al año tras un infarto agudo de miocardio. Resultados del registro PRIAMHO II [Effect of combined beta-blocker and angiotensin-converting enzyme inhibitor treatment on 1-year survival after acute myocardial infarction: findings of the PRIAMHO-II registry]. Rev Esp Cardiol. 2006;59(4):313–320.)
Arós F, Loma-Osorio A, Vila J, et al. Efecto de la asociación de bloqueadores beta e inhibidores de la enzima de conversión en la supervivencia al año tras un infarto agudo de miocardio. Resultados del registro PRIAMHO II [Effect of combined beta-blocker and angiotensin-converting enzyme inhibitor treatment on 1-year survival after acute myocardial infarction: findings of the PRIAMHO-II registry]. Rev Esp Cardiol. 2006;59(4):313–320.Arós F, Loma-Osorio A, Vila J, et al. Efecto de la asociación de bloqueadores beta e inhibidores de la enzima de conversión en la supervivencia al año tras un infarto agudo de miocardio. Resultados del registro PRIAMHO II [Effect of combined beta-blocker and angiotensin-converting enzyme inhibitor treatment on 1-year survival after acute myocardial infarction: findings of the PRIAMHO-II registry]. Rev Esp Cardiol. 2006;59(4):313–320., Arós F, Loma-Osorio A, Vila J, et al. Efecto de la asociación de bloqueadores beta e inhibidores de la enzima de conversión en la supervivencia al año tras un infarto agudo de miocardio. Resultados del registro PRIAMHO II [Effect of combined beta-blocker and angiotensin-converting enzyme inhibitor treatment on 1-year survival after acute myocardial infarction: findings of the PRIAMHO-II registry]. Rev Esp Cardiol. 2006;59(4):313–320.
IntroductionThis study assessed the real-life effectiveness of a single-pill combination (SPC) of bisoprolol/perindopril for controlling blood pressure (BP) and symptoms of angina in patients with hypertension and a history of myocardial infarction (MI).MethodsEligible patients with arterial hypertension and a history of MI were aged 18–79 years and had initiated bisoprolol/perindopril SPC within 3 months of study enrollment as part of routine Russian clinical practice. The primary endpoint was mean change in systolic and diastolic BP (SBP/DBP) at week 12 compared with baseline (data collected retrospectively). Secondary endpoints were assessed at weeks 4 and 12 and included mean change in resting heart rate (HR), proportion of patients reaching target level of resting HR, antianginal effectiveness of the SPC, and proportion of patients reaching target BP levels.ResultsA total of 504 patients were enrolled, of whom 481 comprised the full analysis set (mean age 61.4 ± 8.9 years, 68% men). Mean baseline SBP/DBP and HR values were 148.9 ± 16.8/87.7 ± 11.0 mmHg and 77.4 ± 10.5 bpm, respectively. Mean durations of hypertension and CAD were 12.8 ± 8.4 and 6.1 ± 6.3 years, respectively, and time since MI was 3.8 ± 5.3 years. At week 12, SBP/DBP had decreased by 24.9/12.2 mmHg (P < 0.001 vs baseline). Target BP (< 140/90 mmHg) was achieved by 69.8% and 95.9% of patients at weeks 4 and 12, respectively, and target HR (55–60 bpm) by 17.3% and 34.5% at weeks 4 and 12 versus 3.1% at baseline (P < 0.001). Reductions in angina attacks, nitrate consumption, and improvements in HR were statistically significant. Treatment was well tolerated.ConclusionTreatment of symptomatic patients with CAD, hypertension, and a history of MI with a bisoprolol/perindopril SPC was associated with significant decreases in SBP/DBP and a high proportion of patients achieving BP treatment goals. This was accompanied by improvements in angina symptoms and reductions in HR in a broad patient population representative of those seen in everyday clinical practice.Trial RegistrationClinicalTrials.gov Identifier NCT04656847.
Advances in Therapy – Springer Journals
Published: Apr 8, 2023
Keywords: Angina; Arterial hypertension; Bisoprolol; Blood pressure; Coronary artery disease; Heart rate; Myocardial infarction; Perindopril; Single-pill combination
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.